This website is intended for UK healthcare professionals only.
Adverse event reporting information can be found at the bottom of the page.
Available resources for healthcare professionals
All materials for healthcare professionals are intended to be viewed online. If you wish to download any of these resources, please ensure that you also download the prescribing information.
Healthcare professional videos
Hear from an expert on the LYNPARZA (olaparib) clinical trial data
Professor Noel Clarke, Principal Investigator of the PROpel study, presents the efficacy and safety of LYNPARZA combination treatment for 1L mCRPC.
Length of video: 8 minutes
Expert on Demand
Join our sessions, led by an expert healthcare professional.
Our Expert on Demand programme offers a novel opportunity for healthcare professionals to attend interactive virtual presentations and Q&A sessions. The programme provides a virtual platform to share best practices and discuss topics related to LYNPARZA (olaparib) combination treatment for 1L mCRPC.
- Personal – small group presentations
- Professional – expert clinical presenters
- Practical – ~30-minute presentations
Please see a list of available topics below:
Module 1: New perspectives in the management of mCRPC; LYNPARZA in PROpel
Learn about the evolving landscape of 1L mCRPC therapy and key outcomes from the PROpel clinical trial data for LYNPARZA combination treatment
Module 2: Management of adverse events and monitoring patients on LYNPARZA in combination with abiraterone + prednisone/prednisolone
Examine the safety and tolerability profile of LYNPARZA combination treatment, including management of common and rare but serious adverse events through standard procedures or dose adjustments
Mode of action for LYNPARZA combination therapy
Abbreviations
mCRPC=metastatic castration-resistant prostate cancer; PI=prescribing information.
April 2025 | Job code: GB-65676